Gland Pharma Statistics
Total Valuation
Gland Pharma has a market cap or net worth of INR 314.02 billion. The enterprise value is 299.34 billion.
Market Cap | 314.02B |
Enterprise Value | 299.34B |
Important Dates
The next estimated earnings date is Monday, November 4, 2024.
Earnings Date | Nov 4, 2024 |
Ex-Dividend Date | Aug 16, 2024 |
Share Statistics
Gland Pharma has 164.75 million shares outstanding. The number of shares has increased by 0.00% in one year.
Shares Outstanding | 164.75M |
Shares Change (YoY) | +0.00% |
Shares Change (QoQ) | -0.04% |
Owned by Insiders (%) | 0.01% |
Owned by Institutions (%) | 37.24% |
Float | 73.17M |
Valuation Ratios
The trailing PE ratio is 43.48 and the forward PE ratio is 32.51. Gland Pharma's PEG ratio is 1.60.
PE Ratio | 43.48 |
Forward PE | 32.51 |
PS Ratio | 5.36 |
PB Ratio | 3.60 |
P/FCF Ratio | n/a |
PEG Ratio | 1.60 |
Enterprise Valuation
EV / Earnings | 41.45 |
EV / Sales | 5.11 |
EV / EBITDA | 22.57 |
EV / EBIT | 32.11 |
EV / FCF | n/a |
Financial Position
Current Ratio | n/a |
Quick Ratio | n/a |
Debt / Equity | 4.27 |
Debt / EBITDA | 0.28 |
Debt / FCF | n/a |
Interest Coverage | 34.66 |
Financial Efficiency
Return on Equity (ROE) | n/a |
Return on Assets (ROA) | n/a |
Return on Capital (ROIC) | 6.83% |
Revenue Per Employee | 13.92M |
Profits Per Employee | 1.72M |
Employee Count | 4,217 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +12.69% in the last 52 weeks. The beta is 0.33, so Gland Pharma's price volatility has been lower than the market average.
Beta (5Y) | 0.33 |
52-Week Price Change | +12.69% |
50-Day Moving Average | 1,954.99 |
200-Day Moving Average | 1,866.00 |
Relative Strength Index (RSI) | 47.12 |
Average Volume (20 Days) | 412,162 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Gland Pharma had revenue of INR 58.58 billion and earned 7.22 billion in profits. Earnings per share was 43.84.
Revenue | 58.58B |
Gross Profit | 33.47B |
Operating Income | 9.32B |
Pretax Income | 10.90B |
Net Income | 7.22B |
EBITDA | 13.26B |
EBIT | 9.32B |
Earnings Per Share (EPS) | 43.84 |
Balance Sheet
The company has 18.39 billion in cash and 3.72 billion in debt, giving a net cash position of 14.67 billion or 89.06 per share.
Cash & Cash Equivalents | 18.39B |
Total Debt | 3.72B |
Net Cash | 14.67B |
Net Cash Per Share | 89.06 |
Equity (Book Value) | 87.24B |
Book Value Per Share | 529.54 |
Working Capital | n/a |
Cash Flow
Operating Cash Flow | n/a |
Capital Expenditures | n/a |
Free Cash Flow | n/a |
FCF Per Share | n/a |
Margins
Gross margin is 57.13%, with operating and profit margins of 15.92% and 12.33%.
Gross Margin | 57.13% |
Operating Margin | 15.92% |
Pretax Margin | 18.60% |
Profit Margin | 12.33% |
EBITDA Margin | 22.64% |
EBIT Margin | 15.92% |
FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 20.00, which amounts to a dividend yield of 1.05%.
Dividend Per Share | 20.00 |
Dividend Yield | 1.05% |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -0.00% |
Shareholder Yield | 1.05% |
Earnings Yield | 2.30% |
FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |